A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma ...
Activity of PU-H71, a novel HSP90 inhibitor, and bortezomib in Ewing sarcoma preclinical models. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results